-
WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer
The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with ” Oncology Frontier ,” Dr. Shi Meiqi shared research insights, key results,…
-
WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening
The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo. On the first day, Dr. Chen Haiquan, Director of the Lung Cancer Research Center at Fudan University and Chief of Thoracic Surgery at Fudan University Affiliated Tumor Hospital, gave an important presentation. During an interview with “Oncology Frontier”, Dr. Chen Haiquan…
-
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award
The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam’s research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA’s…
-
WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in…
-
Revisiting the “Gut-Liver-Brain Axis” through the Lens of Bile Acids – Key Advances and Prospects in Basic and Clinical Research
AASLD Roundtable Discussion: Revisiting the “Gut-Liver-Brain Axis” through the Lens of Bile Acids – Key Advances and Prospects in Basic and Clinical Research Editor’s Note: The recently concluded AASLD 2023,…
-
AASLD Interview | Dr.Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development
Editor’s Note: At the just-concluded Annual Summit of Hepatology, the American Association for the Study of Liver Diseases (AASLD2023), Professor Fengmin Lu’s team from Peking University presented three contributions (1…
-
AASLD Exclusive Interview | Professor Monica Tincopa: Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Editor’s Note: At the recently concluded international annual grand event in the field of hepatology – the American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Professor…
-
WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University’s Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the…
Connecting Medical Expertise through Media